Year: 2024
Type: article
Abstract: interactions.WES analysis showed LOH of one HLA-II isotype in 10/76 non-acral cutaneous melanoma samples (2/9 patients), and only in 1/52 acral/mucosal samples (1/5 patients), suggesting immune editing may drive HLA-II loss.Conclusions: Our findings indicate a link between melanoma dedifferentiation, CD4+ TIL recognition via HLA-DR, and HLA-II loss.Recognition of HLA-II+ melanomas is preferentially mediated via HLA-DR, but LOH might impact neoantigen presentation, leading to immune evasion.Clinical trial identification: PEACE study: NCT03004755, study start at 2014/03.Legal entity responsible for the study: The authors.
Source: Immuno-Oncology Technology
Authors: H. Shehade, C. Martinoli, P. Tieppo, N. Rosewick, S. Ma, F. Strozzi, Y. McGrath, M. Rossetti
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374805